FIELD: chemistry.
SUBSTANCE: invention relates to application of 5-amino-3-(2-aminopropyl)-[1,2,4]thiadiazole derivatives of general formula (I) 
as cytostatic preparations for fighting oncologic process in form of bases or pharmacologically acceptable salts. In formula (I) R1, R2 can be similar or different and independently represent hydrogen, halogen, alkyl, R3 represents alkyl, aralkyl, heteroalkyl, cycloalkyl.
EFFECT: increased efficiency of composition application.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW DRUGS WITH CYTOTOXIC ACTIVITY BASED ON AZOLOAZINE DERIVATIVES FOR BREAST CANCER CHEMOTHERAPY | 2022 |
|
RU2814965C2 |
| RADIOPROTECTIVE, RADIOMITIGATORY AND RADIOSENSITIZING AGENT BASED ON SODIUM SALT OF AMINODIHYDROPHTHALAZINEDIONE SODIUM (DRUG TAMERON) AND OTHER ALKALI AND ALKALINE EARTH METAL SALTS OF AMINODIHYDROPHTHALAZINEDIONE | 2022 |
|
RU2804886C1 |
| AGENT POSSESSING CYTOTOXIC ACTIVITY | 2019 |
|
RU2714932C1 |
| 4-(2,4-DIMETHOXYPHENYL)-2-(2-HYDROXYPHENYL)-5,6-DIHYDRO-4N-BENZO[H]CHROMENE-3-CARBOXYLIC ACID, HAVING CYTOTOXIC ACTIVITY | 2019 |
|
RU2707972C1 |
| METHOD AND COMPOSITION FOR CANCER DISEASE TREATMENT, TOSYLATE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-N'-(4-(2-(N-METHYLCARBAMOYL)-4-PYRIDYLOXY)PHENYL)UREA | 2002 |
|
RU2316326C2 |
| ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT | 2006 |
|
RU2448703C2 |
| DEOXYDERIVATIVES OF CYTIDINE OR URIDINE FOR USE IN THE TREATMENT OF CANCER | 2020 |
|
RU2797489C2 |
| 2-(1,1-DIMETHYL-1H-BENZO[E]INDOLIN-2-YL)-5,6,7-TRICHLORO-1,3-TROPOLONE, WHICH HAS CYTOTOXIC ACTIVITY AGAINST A431 SKIN CANCER AND H1299 LUNG CANCER CELL CULTURES | 2023 |
|
RU2810581C1 |
| PHARMACEUTICAL COMPOSITION EXHIBITING CYTOTOXICITY TOWARDS HUMAN COLON CARCINOMA CELLS | 2020 |
|
RU2747147C1 |
| NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
